Reetu Thakur

Reetu Thakur

Auto-generated profile, based on publicly available information

Reetu Thakur

Cedars-Sinai Medical Center, Smidt Heart Institute , 127 S San Vicente Blvd Pavilion, Los Angeles, CA 90048, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2022 in Matrix Biology
Verified
Journal Article
Closed access
CHChengqun Huang
Chengqun Huang
ASAnkush Sharma
Ankush Sharma
RTREETU THAKUR
REETU THAKUR
DRDeepika Rai
Deepika Rai
MKMadhusudhanarao Katiki
Madhusudhanarao Katiki
HPHonit Piplani
Honit Piplani

27 November 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LALizhuo Ai
Lizhuo Ai
JGJuliana de Freitas Germano
Juliana de Freitas Germano
CHChengqun Huang
Chengqun Huang
MAMarianne Aniag
Marianne Aniag
SSSavannah Sawaged
Savannah Sawaged
JEJennifer Van Eyk
Jennifer Van Eyk
Almost 30% of survivors of myocardial infarction (MI) develop heart failure (HF), in part due to damage caused by the accumulation of dysfunctional mitochondria. Organelle quality control through Parkin-mediated mitochondrial autophagy (mitophagy) is known to play a role in mediating protection against HF damage post-ischaemic injury and remodelling of the subsequent deteriorated myocardium. This study has shown that a single i.p. dose (2 h post-MI) of the selective small molecule Parkin activator PR-364 reduced mortality, preserved cardiac ejection fraction, and mitigated the progression of HF. To reveal the mechanism of PR-364, a multi-omic strategy was deployed in combination with classical functional assays using in vivo MI and in vitro cardiomyocyte models. In vitro cell data indicated that Parkin activation by PR-364 increased mitophagy and mitochondrial biogenesis, enhanced adenosine triphosphate production via improved citric acid cycle, altered accumulation of calcium localization to the mitochondria, and initiated translational reprogramming with increased expression of mitochondrial translational proteins. In mice, PR-364 administered post-MI resulted in widespread proteome changes, indicating an up-regulation of mitochondrial metabolism and mitochondrial translation in the surviving myocardium. This study demonstrates the therapeutic potential of targeting Parkin-mediated mitophagy using PR-364 to protect surviving cardiac tissue post-MI from progression to HF. Parkin activator proposed therapeutic mechanisms. Inactive Parkin (red) is activated by PR-364; activated Parkin (green) promotes enhanced mitophagy and mito-biogenesis, improves mitochondrial function via increased mitochondrial calcium level and biogenesis, and ultimately leads to limited post-myocardial infarction cardiac remodelling and heart failure. MI, myocardial infarction.

1 January 2018 in Translational Research in Oral Oncology
Verified
Journal Article
Open access
VNVishalakshi Nanjappa
Vishalakshi Nanjappa
RRRemya Raja
Remya Raja
ARAneesha Radhakrishnan
Aneesha Radhakrishnan
AJAnkit Jain
Ankit Jain
KDKeshava K Datta
Keshava K Datta
ACAditi Chatterjee
Aditi Chatterjee
Objectives: To identify potential candidate proteins which are secretory in nature and present at a higher abundance in oral cancer patients with tobacco habits. Methods: Conditioned media of tobacco-treated and -untreated non-neoplastic oral keratinocytes were analyzed using iTRAQ-based mass spectrometry. Hypersecreted proteins; SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1 (SPOCK1); prosaposin (PSAP); and protein tyrosine phosphatase, receptor type S (PTPRS) were validated by enzyme-linked immunosorbent assay (ELISA) using saliva samples from oral cancer patients who are tobacco users. Results: Proteomic analysis of tobacco-treated and -untreated cells led to the identification of 2873 proteins. Among these, 378 proteins showed high abundance and 253 proteins showed low abundance (2-fold cutoff) in conditioned-media of tobacco-treated cells. ELISA-based validation showed significantly higher levels of SPOCK1, PSAP, and PTPRS in oral cancer patients with tobacco chewing habits compared to healthy controls. However, PSAP showed low specificity compared to SPOCK1 and PTPRS. Conclusions: This study indicates significantly increased levels of SPOCK1, PSAP, and PTPRS in saliva of oral cancer patients with tobacco habits. These protein biomarkers might be useful to identify tobacco users with high risk of developing oral cancers.

12 June 2020 in Indian Journal of Clinical Biochemistry
Verified
Journal Article
Open access
PDF file
AJAnu Jain
Anu Jain
SMSumanth Kumar Mallupattu
Sumanth Kumar Mallupattu
RTREETU THAKUR
REETU THAKUR
SMSatyawati Mohindra
Satyawati Mohindra
ABAmanjit Bal
Amanjit Bal
Arnab PalArnab Pal
Arnab Pal
Cripto-1 (CR-1) is an oncofetal protein with its role as a key factor in early process of carcinoma has been evaluated in cases of various cancers. However, very few studies have reported its role in oral cancer, which is the sixth most common cancer around the world, particularly with high prevalence in developing countries. Oral squamous cell carcinoma (OSCC) is the most predominant (90%) of all the histological types of oral cancer. Late detection, associated with increased morbidity and mortality, is mainly attributed to non-availability of a suitable biomarker for the disease. In the present pilot study, we have evaluated the role of soluble CR-1, in serum as a potential tumor marker for OSCC. CR-1 was estimated using sandwich ELISA in serum samples of 50 biopsy proven OSCC patients (pre and post treatment) along with age and gender matched healthy controls. Immunohistochemistry was also done in corresponding tumor tissue sections to check the expression of CR-1. Pre-treatment CR-1 was found to be 2.25-fold higher in serum of OSCC patients as compared to control (p < 0.0001***), which was reduced to 1.6 folds post treatment (p = 0.0006***). CR-1 levels were comparatively higher in early stage of disease. Upon IHC 80% of the cases were found to be positive for CR-1. This study provides evidence that serum levels of CR-1 are elevated in patients of Oral Squamous Cell Carcinoma, which decrease post treatment. Also, the association of expression of protein with tumor progression predicts CR-1 as a molecule that can be further evaluated as a potential tumor maker in OSCC.

11 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DRDeepika Rai
Deepika Rai
MBMukta Basu
Mukta Basu
LMLiam McCarthy
Liam McCarthy
DGDivya Gupta
Divya Gupta
ADAshley Dinh
Ashley Dinh
SPSarah J Parker
Sarah J Parker
Myocardial-Infarction (MI) remains a leading cause of mortality worldwide, despite advancements in clinical therapies and interventions. MI results from prolonged ischemia, leading to hypoxia-induced damage to cardiac tissue and reperfusion-injury (R/I) that aggravates cardiomyocyte (CM) loss. One key cellular event during this process is the accumulation of dysfunctional mitochondria, resulting from environmental hypoxia and subsequent oxidative stress upon reperfusion. Post-MI cardiac-remodeling involves changes in both cellular and extracellular matrix (ECM). Ubiquitin-dependent and independent autophagy are crucial for cardio-protection during this phase. Asporin (ASPN), a small leucine-rich proteoglycan, modulates cardiac remodeling by limiting excessive fibrosis and protecting CMs from cell death. We investigated the therapeutic potential of ASPN using an exogenous recombinant ASPN-peptide (rASPN) and tested its effects in an in-vitro ischemia-reperfusion (I/R) model simulating MI conditions. Two I/R models were developed using an immortalized human embryonic cardiac cell line to reflect the hypoxia-reperfusion (H/R) phases of MI. In the No-Reoxygenation (No-ReOx) model, cells were subjected to hypoxia for 18-hours, with or without exogenous rASPN. In the Reoxygenation (ReOx) model, cells underwent 18-hours of hypoxia, followed by 12-hours of reoxygenation (simulating reperfusion), with or without rASPN. Proteomics revealed that ASPN modulates pathways involved in apoptosis, non-canonical autophagy, and metabolic reprogramming. Additionally, ASPN influenced immune-response pathways and significantly affected TGF-β signaling, a central mediator of cardiac fibrosis and remodeling post-MI. Our study demonstrates that rASPN confers protection in a human cardiac cell-based H/R model, highlighting its therapeutic potential as a biological or peptide-based intervention to mitigate R/I and adverse remodeling following MI.

8 July 2019 in medRxiv
Verified
Preprint
Open access
PDF file
AJAnu Jain
Anu Jain
MKMallupattu Sumanth Kumar
Mallupattu Sumanth Kumar
RTREETU THAKUR
REETU THAKUR
MSMohindra Satyawati
Mohindra Satyawati
ABAmanjit Bal
Amanjit Bal
Arnab PalArnab Pal
Arnab Pal
PURPOSE: CR-1 (CR-1) is an oncofetal protein with its role as a key factor in early process of carcinoma has been evaluated in cases of various cancers. However, very few studies have reported its role in oral cancers, which is the sixth most common cancer around the world, particularly with high prevalence in developing countries. Oral squamous cell carcinoma (OSCC) is the most predominant (90%) of all the histological types of oral cancer. Late detection, associated with increased morbidity and mortality, is mainly attributed to non-availability of a suitable biomarker for the disease. In the present pilot study we have evaluated the role of soluble CR-1, in serum as a potential tumor marker for OSCC. METHODS: CR-1 was estimated using sandwich ELISA in serum samples of 50 biopsy proven OSCC patients (pre and post treatment) along with age and gender matched healthy controls. Immunohistochemistry was also done in corresponding tumor tissue sections to check the expression of CR-1. RESULTS: Pre-treatment CR-1 was found to be 2.25 fold higher in serum of OSCC patients as compared to control (p<0.0001***), which was reduced to 1.6 folds post treatment (p=0.0006***). CR-1 levels were comparatively higher in early stage of disease. Upon IHC 80% of the cases were found to be positive for CR-1. CONCLUSION: This study provides evidence that serum levels of CR-1 are elevated in patients of Oral Squamous Cell Carcinoma, which decrease post treatment. Also, the association of expression of protein with tumor progression predicts CR-1 as a molecule that can be further evaluated as a potential tumor maker in OSCC.